Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-24
2006-10-24
Kim, Vickie (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07125866
ABSTRACT:
Benzodiazepinc compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures (I) or (II): wherein R1, R2, R3and R4are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.
REFERENCES:
patent: 4076823 (1978-02-01), Wade et al.
patent: 4088756 (1978-05-01), Voorhees
patent: 4110337 (1978-08-01), Szarvasi
patent: 4495101 (1985-01-01), Klaubert et al.
patent: 4751223 (1988-06-01), Glamkowski et al.
patent: 5041438 (1991-08-01), Hsu
patent: 5216148 (1993-06-01), Klaus et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5324726 (1994-06-01), Bock et al.
patent: 5591227 (1997-01-01), Dihn et al.
patent: 5597915 (1997-01-01), Chambers et al.
patent: 5599352 (1997-02-01), Dihn et al.
patent: 5697967 (1997-12-01), Dihn et al.
patent: 5776946 (1998-07-01), McGeer et al.
patent: 5861380 (1999-01-01), Gyorkos et al.
patent: 6004942 (1999-12-01), Firestein et al.
patent: 6080588 (2000-06-01), Glick
patent: 6277844 (2001-08-01), Spector et al.
patent: 6319931 (2001-11-01), Kroemer et al.
patent: 6506744 (2003-01-01), Alig
patent: 6767533 (2004-07-01), Casellas
patent: 2001/0016583 (2001-08-01), Glick et al.
patent: 2003/0044776 (2003-03-01), Dykens et al.
patent: 2006/0025388 (2006-02-01), Glick
patent: 1810423 (1969-10-01), None
patent: 0 227 539 (1986-12-01), None
patent: 0 349 949 (1990-01-01), None
patent: WO 90/13332 (1990-11-01), None
patent: WO 91/12779 (1991-09-01), None
patent: WO 99/29347 (1999-06-01), None
patent: WO 99/58117 (1999-11-01), None
patent: WO 00/19200 (2000-06-01), None
Gupta et al., Psychitripic drugs in drmatology . . . ,, Database:EMbase(AN:86111413), Journal of the American Academy of Dermatology, 1986, vol. 14, No. 4, pp. 633-645.
Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484.
Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259.
Parks, Daniel J. Bioorg Med Chem. Ltrs,. 15,(2005), 765-770.
Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861.
Hulme, C. J. Org. Chem., 63,(1998), 8021-8023.
Kamal, A. Synlett, 14,(2004), 2533-35.
Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912.
Beurdeley-Thomas et al., Journal of Neuro-Oncology 46 (2000) 45-56.
Churcher et al., Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-183.
Darrow et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132.
Herranz, Medicinal Research Reviews 23 (2003) 559-603.
Ramdas et al., Archieves of Biochemistry and Biophysics 368 (1999) 394-400.
Ursini et al., J. Med. Chem. 43 (2000) 3596-3613.
Walser et al., J. Org. Chem. 38:3502-3507 (1973).
Kim et al., J. Braz. Chem. Soc. 9:375-379 (1998).
Schlumpf, M., et al., “Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines,” Toxic. In Vitro—8(5):1061-1065(1994).
Blum P., et al., “Stiff-Person Syndrome: An Autoimmune Disease”Movement Disorders, 6 (1): 12-20 (1991).
Malgrange B., et al., “Beta-Carbolines Induce Apoptotic Death of Cerebellar Granule Neurones in Culture”Neuroreport, 7 (18): 3041-3045 (1996).
Miller, K.A., et al., “Benzodiazepines Prevent Neuronal Death By Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia”Society for Neuroscience Abstracts, 24 (1-2): 979 (1998).
Schlumpf M., et al., “Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines”Toxic in Vitro, 8 (5): 1061-1065 (1994).
Tanimoto Y., et al., “Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential”Jpn. J. Pharmacol., 79: 177-183 (1999).
Taupin V., et al., “Endogenous Anxiogenic Peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes”Lymphokine and Cytokine Research, 10 (1): 7-13 (1991).
Blum, P., et al., “Stiff-Person Syndrome: An Autoimmune Disease,”Movement Disorders—6(1):12-20 (1991).
Malgrange, B., et al., “β-Carbolines Induce Apoptotic Death of Cerebellar Granule Neurones in Cultures,”NeuroReport—7(18):3041-3045 (1996).
Miller, K.A., et al., “Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis in the Gerbil Hippocampus Following Transient Cerebral Ischemia,”Society for Neuroscience Abstracts—24(1-2):979 (1998).
Schlumpf, M., et al., “Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines,”Toxic. In Vitro—3(5):1061-1065 (1994).
Tanimoto, Y., et al., “Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial Transmembrane Potential,”Jpn. J. Pharmacol.—79:177-183 (1999).
Taupin, V., et al., “Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines Enhance the Production of Interleukin-1 and Tumor Necrosis Factor by Human Monocytes,”Lymphokine and Cytokine Research—10(1):7-13 (1991).
Adachi, M., et al., “Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene oflprMice,”Proc. Natl. Acad. Sci. USA—90:1756-1760 (1993).
Adelman, N.E., et al., “Treatment of (NZB X NZW)F1Disease with Anti-I-A Monoclonal Antibodies,”J. Exp. Med.—158:1350-1355 (1983).
Baader, S.L., et al., “Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N-SH) and Neuroectodermal (SK-N-LO) Cells,”Anticancer Research—14:221-228 (1994).
Beale, P.J., et al., “BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma,”British Journal of Cancer—82(2):436-440 (2000).
Boojamra, C.G., et al., “Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality,”J. Org. Chem.—62:1240-1256 (1997).
Bunin, B.A., et al., “A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives,”J. Am. Chem. Soc.—114:10997-10998 (1992).
Bunin, B.A., et al., “The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library,”Proc. Natl. Acad. Sci. USA—91:7408-4712 (1994).
Chumakov, A.M., et al., “Analysis of p53 Transactivation Through High-Affinity Binding Sites,”Oncogene—8:3005-3011 (1993).
Cohen, P.L., et al., “Lprandgld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease,”Annu. Rev. Immunol.—9:243-269 (1991).
Crabtree, R.H., “A New Type of Hydrogen Bond,”Science—282:2000-2001 (1998).
Desoize, B., “Anticancer Drug Resistance and Inhibition of Apoptosis,”Anicancer Research—14:2291-2294 (1994).
Doble, A., et al., “Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [3H]PK 11195: Anatomical and Subcellular Distribution,”Brain Research Bulltetin—18:49-61 (1987).
Donadio, J.V., et al., “Immunosuppressive Drug Therapy in Lupus Nephritis,”American Journal of Kidney Diseases—21(3):239-250 (1993).
Ermak, T.H., et al., “Treatment of Murine Lupus with Monoclonal Antibody to L3T4,”Laboratory Investigation—61(4):447-456 (1989).
Gallant, J.E., et al.,“Incidence and Natural History o
Glick Gary D.
Opipari, Jr. Anthony W.
Kim Vickie
Medlen & Carroll LLP
Regents of the University of Michigan
LandOfFree
Therapeutic applications of pro-apoptotic benzodiazepines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic applications of pro-apoptotic benzodiazepines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic applications of pro-apoptotic benzodiazepines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676003